Department of Oncology, Jinan Central Hospital, Shandong University, 250013, Jinan, Shandong, China.
Department of Radiation Oncology, Shandong Key Laboratory of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, No. 440 Jiyan Road, 250117, Jinan, Shandong, China.
Strahlenther Onkol. 2018 Dec;194(12):1152-1162. doi: 10.1007/s00066-018-1362-7. Epub 2018 Sep 14.
This study aimed to determine the risk factors for brain metastasis (BM) and the prognostic factors for overall survival (OS) in patients with small cell lung cancer without prophylactic cranial irradiation (PCI).
Limited stage small cell lung cancer (LS-SCLC) patients achieving a complete response (CR) or partial response (PR) were enrolled into this study between January 2010 and December 2016. We retrospectively evaluated the influencing factors for time to BM and overall survival (OS).
A total of 153 patients were enrolled into this study. Sixty-eight developed BM during the follow-up period. For the whole cohort, the 1‑ and 2‑year BM rates were 29.4 and 41.2%, respectively. Multivariate analysis showed that T stage (hazard ratio [HR] = 2.27, P = 0.024), neutrophil-to-lymphocyte ratio (NLR; HR = 2.07, P = 0.029), time to thoracic radiotherapy (HR = 0.34, P = 0.002) and chemotherapy cycles (HR = 0.49, P = 0.036) were the independent influencing factors of time to BM. Only NLR (HR = 2.11, P = 0.005) and time to thoracic radiotherapy (HR = 1.95, P = 0.011) were independent prognostic factors of OS. Of the 68 patients developing BM, those with BM occurring as the first relapse (42/68) had better OS than the others (39.5 months vs 23.0 months, P = 0.016).
LS-SCLC patients without PCI had a high risk of BM. High T stage, high NLR, early thoracic radiotherapy and fewer chemotherapy cycles were the risk factors of BM. Further research is needed to confirm the results.
本研究旨在确定未经预防性颅脑照射(PCI)的小细胞肺癌(SCLC)患者发生脑转移(BM)的风险因素和总生存(OS)的预后因素。
2010 年 1 月至 2016 年 12 月,本研究纳入了局限期小细胞肺癌(LS-SCLC)患者,这些患者达到完全缓解(CR)或部分缓解(PR)。我们回顾性评估了影响 BM 发生时间和总生存(OS)的因素。
共纳入 153 例患者。在随访期间,68 例患者发生 BM。对于整个队列,1 年和 2 年的 BM 发生率分别为 29.4%和 41.2%。多因素分析表明,T 分期(风险比[HR] = 2.27,P = 0.024)、中性粒细胞与淋巴细胞比值(NLR;HR = 2.07,P = 0.029)、胸部放疗时间(HR = 0.34,P = 0.002)和化疗周期(HR = 0.49,P = 0.036)是 BM 发生时间的独立影响因素。仅 NLR(HR = 2.11,P = 0.005)和胸部放疗时间(HR = 1.95,P = 0.011)是 OS 的独立预后因素。在发生 BM 的 68 例患者中,BM 作为首次复发的患者(42/68)的 OS 优于其他患者(39.5 个月 vs 23.0 个月,P = 0.016)。
未经 PCI 的 LS-SCLC 患者发生 BM 的风险较高。高 T 分期、高 NLR、早期胸部放疗和较少的化疗周期是 BM 的危险因素。需要进一步的研究来证实这些结果。